Our professionals
Dr. Miguel Fernández de Sanmamed Gutiérrez
Principal Investigator of the Onco-Applied and Translational Immunology group.
Preferential dedication on cancer immunotherapy, with special attention to skin and lung cancer, hummanized PDX models and new circulating biomarkers.
Professional career
Specialist in the Department of Medical Oncology at the Clínica Universidad de Navarra, Co-Coordinator of the Skin Tumor Area at the University of Navarra Cancer Center and Principal Investigator in the Immunology and Immunotherapy Program at the Cima University of Navarra since 2018.
CyTOF training (exposure) Stanford University, USA (2014).
Postdoctoral fellow in the Immunobiology program at Yale University (USA) from 2013 to 2018.
Post-doctorate at the University of Navarra with a Rio Ortega contract (2011-2013).
He specialized in Medical Oncology at the Hospital Universitario Central de Asturias (Oviedo, 2010).
Degree (2005) in Medicine and Surgery from the University of Santiago de Compostela and PhD (2011) in Medicine from the University of Oviedo.
RESEARCH AREAS
- 2023: Highly cited researcher by Web of Science Group (Clarivate).
- 2023-Currently: CRIS Excellence Program. Cris contra el cáncer
- 2022: imCORE Early carrer Networking. imFLAME investigator award.
- 2021-Currently: Asociación Española contra el Cáncer. LAB AECC.
- 2020-2022: Asociación Española contra el Cáncer. Clinical Junior (Mentor)
- 2019-Currently: Spanish Govern. Ministry of Education. FIS.
- 2018-Currently: Spanish Govern. Ministry of Education. Miguel Servet Contract.
- 2018-2019: Spanish Society of Medical Oncology. Beca de Retorno.
- 2016: European Society of Medical Oncology (ESMO). Annual Meeting Travel Award
- 2016: SITC and Astra Zeneca. Cancer Immunotherapy Clinical Fellowship in NSCLC
- 2013-2015: Spanish Society of Medical Oncology. Translational Research Fellowship
- 2011-2013: Spanish Govern. Ministry of Education. Rio Hortega Translational Research Scholarship.
- 2011: Spanish Society of Medical Oncology Annual Meeting. Best Oral Communication Award
AREAS OF INTEREST
-
Cancer immunotherapy with special focus in skin and lung cancer (Interleukin-8, T-cell engagers, Bi-scpecific mAbs)
-
Hummanized-PDX models (Optimization of the model, Application to investigate new Treg target therapies, Implementation of T-cell and non T-cell inflamed models)
-
Circulating new biomarkers (Exosomes, Anti-drug antibodies)
Activity
As an educator
- 2019-Currently: Assistant Professor. University of Navarra School of Medicine.
- 2018-Currently: Adjunct Assistant Professor. Oncology Department. Yale School of Medicine.
- 2021-2022: Supervisor of Masther´s Thesis of Cyril Puyo Uriarte. “LILRB2/HLA-G pathway as a new target in cancer immunotherapy”. Uniiiiiiiversity of Navarra, Spain. Academic year: 2021-2022
- 2020-2021: Co-supervisor of Masther´s Thesis of Jose Mario Rojas Morales. “Anti-drug-antibodies (ADA) as a mechanism of resistance in cancer immunotherapy”. University of Navarra, Spain. Academic year: 2020-2021
- 2019-2020: Co-supervisor of Masther´s Thesis of María Romay Egurrechea. “Identification of tumour exosomes as a tool of analysis in humanized PDX model”. University of Navarra, Spain. Academic year: 2019-2020
- 2018-2019: Supervisor of Master´s Thesis of Inmaculada Aguilera Buenosvinos. “Alternative hu-PBMC/Immunoavatar mouse models to study cancer immunotherapies with minimal graft-versus-host disease”. University of Navarra, Spain. Academic year: 2018-2019.
- 2016: Co-supervision of Thesis of Omar Carranza. PhD Student. Project: “Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins”. University of Navarra, Spain. Highest degree.
- 2015-2016: Assistant in the Immunobiology Department. Yale University.
- 2010-2013: Assistant in the Immunology Department. University of Navarra
- 2009-2011: Assistant in the Internal Medicine Department. University of Oviedo
As a researcher
- Author of more than 70 articles published in international scientific journals.
- Collaborator in more than 5 chapters of books in the specialty.
Scientific Institutions
- Member of the Board of Directors of ASEICA.
- ESMO Faculty Member for the Translational Research.
Scientific Institutions
- 2016 | European Society of Medical Oncology (ESMO). Annual Meeting Travel Award.
- 2011 | Spanish Society of Medical Oncology Annual Meeting. Best Oral Communication Award.
More information
Latest scientific publications
- MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers. Scientific Publication Sep 6, 2024 | Magazine: Journal for Immunotherapy of Cancer
- Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment. Scientific Publication Jul 17, 2024 | Magazine: Archivos de Bronconeumología